中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2011年
12期
885-890
,共6页
张旗%何湘君%马丽萍%李娜%杨静%成夜霞%崔恒
張旂%何湘君%馬麗萍%李娜%楊靜%成夜霞%崔恆
장기%하상군%마려평%리나%양정%성야하%최항
微小RNA%p53通路%卵巢肿瘤
微小RNA%p53通路%卵巢腫瘤
미소RNA%p53통로%란소종류
MicroRNA%P53 pathway%Ovarian neoplasms
目的 探讨微小RNA (miRNA) miR-449a、miR-449b和miR-192家族是否与miR-34家族一样可作为p53通路成员,在卵巢癌中发挥作用.方法 以DNA损伤药物阿霉素处理p53野生型卵巢癌A2780细胞,采用Western blot法检测A2780细胞中p53蛋白的表达改变,采用实时定量PCR法检测激活p53后miR-449a/b、miR-34a、miR-34b、miR-34c、miR-192和miR-194的表达.在P53突变型卵巢癌SKOV3.ipl细胞中过表达miRNA,检测SKOV3.ipl细胞的细胞周期改变.采用实时定量PCR法检测miR-449a/b、miR-34a、miR-34b、miR-34c、miR-192和miR-194在正常输卵管以及不同分级分期的浆液性卵巢癌组织中的表达.结果 在阿霉素处理后24h,卵巢癌A2780细胞中p53蛋白的表达明显升高,miR-34b、miR-34c、miR-449a/b的表达约升高19 ~ 21倍,但miR-192和miR-194的表达未见明显变化.转染miR-449b和miR-34c后,SKOV3.ipl细胞出现G1期阻滞.miR-449a/b在浆液性卵巢癌组织中的表达改变与miR-34b和miR-34c基本平行,它们在高级别和晚期浆液性卵巢癌组织中的表达水平,显著低于正常输卵管组织以及低级别和早期浆液性卵巢癌组织;miR-192、miR-194和miR-34a在卵巢癌组织中的表达未发现明显的特征,在正常输卵管组织中的表达也明显低于miR-449a/b、miR-34b和miR-34c.结论 miR-449a/b与miR-34b、miR-34c作为抑癌基因,在p53通路中发挥协同作用,它们的功能缺失与浆液性卵巢癌的发生、发展密切相关.
目的 探討微小RNA (miRNA) miR-449a、miR-449b和miR-192傢族是否與miR-34傢族一樣可作為p53通路成員,在卵巢癌中髮揮作用.方法 以DNA損傷藥物阿黴素處理p53野生型卵巢癌A2780細胞,採用Western blot法檢測A2780細胞中p53蛋白的錶達改變,採用實時定量PCR法檢測激活p53後miR-449a/b、miR-34a、miR-34b、miR-34c、miR-192和miR-194的錶達.在P53突變型卵巢癌SKOV3.ipl細胞中過錶達miRNA,檢測SKOV3.ipl細胞的細胞週期改變.採用實時定量PCR法檢測miR-449a/b、miR-34a、miR-34b、miR-34c、miR-192和miR-194在正常輸卵管以及不同分級分期的漿液性卵巢癌組織中的錶達.結果 在阿黴素處理後24h,卵巢癌A2780細胞中p53蛋白的錶達明顯升高,miR-34b、miR-34c、miR-449a/b的錶達約升高19 ~ 21倍,但miR-192和miR-194的錶達未見明顯變化.轉染miR-449b和miR-34c後,SKOV3.ipl細胞齣現G1期阻滯.miR-449a/b在漿液性卵巢癌組織中的錶達改變與miR-34b和miR-34c基本平行,它們在高級彆和晚期漿液性卵巢癌組織中的錶達水平,顯著低于正常輸卵管組織以及低級彆和早期漿液性卵巢癌組織;miR-192、miR-194和miR-34a在卵巢癌組織中的錶達未髮現明顯的特徵,在正常輸卵管組織中的錶達也明顯低于miR-449a/b、miR-34b和miR-34c.結論 miR-449a/b與miR-34b、miR-34c作為抑癌基因,在p53通路中髮揮協同作用,它們的功能缺失與漿液性卵巢癌的髮生、髮展密切相關.
목적 탐토미소RNA (miRNA) miR-449a、miR-449b화miR-192가족시부여miR-34가족일양가작위p53통로성원,재란소암중발휘작용.방법 이DNA손상약물아매소처리p53야생형란소암A2780세포,채용Western blot법검측A2780세포중p53단백적표체개변,채용실시정량PCR법검측격활p53후miR-449a/b、miR-34a、miR-34b、miR-34c、miR-192화miR-194적표체.재P53돌변형란소암SKOV3.ipl세포중과표체miRNA,검측SKOV3.ipl세포적세포주기개변.채용실시정량PCR법검측miR-449a/b、miR-34a、miR-34b、miR-34c、miR-192화miR-194재정상수란관이급불동분급분기적장액성란소암조직중적표체.결과 재아매소처리후24h,란소암A2780세포중p53단백적표체명현승고,miR-34b、miR-34c、miR-449a/b적표체약승고19 ~ 21배,단miR-192화miR-194적표체미견명현변화.전염miR-449b화miR-34c후,SKOV3.ipl세포출현G1기조체.miR-449a/b재장액성란소암조직중적표체개변여miR-34b화miR-34c기본평행,타문재고급별화만기장액성란소암조직중적표체수평,현저저우정상수란관조직이급저급별화조기장액성란소암조직;miR-192、miR-194화miR-34a재란소암조직중적표체미발현명현적특정,재정상수란관조직중적표체야명현저우miR-449a/b、miR-34b화miR-34c.결론 miR-449a/b여miR-34b、miR-34c작위억암기인,재p53통로중발휘협동작용,타문적공능결실여장액성란소암적발생、발전밀절상관.
Objective The aim of this study was to investigate whether miR-449a,miR-449b and miR-192 family microRNAs play the same roles in p53 pathway as miR-34 family in ovarian cancer.Methods Wild-type p53 ovarian carcinoma cell line A2780 cells were treated with genotoxic agent adriamycin.The reactivation of p53 was detected by Western blot.The expression of miR-449a/b,miR-34a,miR-34b,miR-34c,miR-192 and miR-194 were detected by real-time quantitative PCR.Mutant p53 ovarian cancer cell line SKOV3.ipl cells were transfected with pre-microRNAs and the cell-cycle changes were detected.The expression level of miR-449a/b,miR-34a,miR-34b,miR-34c,miR-192 and miR-194 in serous ovarian carcinomas of varying grade and stage were compared with real-time PCR.Results The expressions of miR-449a/b,miR-34b and miR-34c were 19-fold to 21-fold elevated after p53 activation by genotoxic agent. Ectopic expression of miR-449b,as well as miR-34c,resulted in cell-cycle arrest in SKOV3.ipl cells.The expression of miR-449a/b was parallel with that of miR-34b,miR-34c,and were significantly lower in late stage and high-grade serous carcinomas than in the normal fallopian tube,early stage and low-grade serous carcinomas.The expression of miR-192,miR-194 and miR-34a did not show evident features in serous ovarian carcinomas and were much lower than miR-449a/b,miR-34b and miR-34c in normal fallopian tube.Conclusions As tumor-suppressor microRNAs,miR-449a/b,miR-34b and miR-34c cooperate and play important roles in p53 pathway. Their inactivation may contribute to the carcinogenesis and progression of serous ovarian carcinomas.